US Federal Circuit reverses and remands 2008 Mirapex patent validity opinion
This article was originally published in Scrip
Executive Summary
A federal appeals court has handed a win to Boehringer Ingelheim in a patent infringement case, and has reversed and remanded a 2008 ruling from a lower court that invalidated a US patent related to the company's Parkinson's disease treatment, Mirapex (pramipexole dihydrochloride), for obviousness-type double patenting.